These studies had led to new cholesterol guidelines in the U.S. that suggested lowering low-density lipoprotein (LDL), or bad cholesterol, to extemely low levels.
The medicine worked incredibly well, lowering low-density lipoprotein (LDL), the bad cholesterol, by 70%.
FORBES: How A Mourning Entrepreneur And A Dogged Doctor Rescued A Rare Disease Drug
Most of the time low-density lipoprotein (LDL), better known as "bad cholesterol, " sits around doing little.
"I'm confused, " he says, because reducing low-density lipoprotein (LDL), or bad cholesterol, is such a cornerstone of cardiology.
Low-density lipoprotein (LDL) or bad cholesterol levels should be below 100, and high-density lipoprotein (HDL) should measure 35 or above.
Up until now, evidence for statins has been mainly in people with high "bad" cholesterol, properly known as low-density lipoprotein (LDL).
Big studies have shown that low HDL levels may be as important as high levels of low-density lipoprotein (LDL) in causing heart attacks.
Vytorin lowers low-density lipoprotein (LDL) more than any other single pill.
But when Zetia was combined with a statin like Lipitor or Zocor, it lowered bad cholesterol, or low-density lipoprotein (LDL), more than anything else out there.
Both work by inhibiting an obscure molecule called the cholesterol ester transfer protein (CETP) that works indirectly to prevent HDL from being used to create low-density lipoprotein (LDL), the bad cholesterol.
For patients at the highest risk of heart attack, the new guidelines suggest that "bad cholesterol, " or low-density lipoprotein (LDL), be reduced to 70 mg per deciliter--although the new guideline is optional.
Zetia (generically known as ezetimibe) lowers low-density lipoprotein (LDL), the bad cholesterol involved in causing heart attacks and strokes, but less so than existing drugs like Lipitor (generically known as atorvastatin), Crestor, from AstraZeneca, or simvastatin.
FORBES: Merck's Cholesterol Pill Win Is Already Drawing Fire
KYNAMRO, given as a 200 mg weekly subcutaneous injection, has been approved as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia
The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).
FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia
The most common type of cholesterol problem is a high LDL (low density lipoprotein) which is usually best treated with a statin, of which there are at least four on the market.
Schering and Merck have defended the drugs by pointing to the mountains of evidence that support the idea that lowering low-density lipoprotein, commonly known as LDL or "bad cholesterol, " prevents heart attacks.
应用推荐